The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer

The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer

<b>Introduction</b>: Non-small cell lung cancer (NSCLC) is the second most common cancer globally. The mesenchymal-epithelial transition (MET) proto-oncogene can be targeted in NSCLC patients. <b>Methods</b>: We performed a literature search on PubMed in December 2019 for stu...

Full description

Bibliographic Details
Main Authors:	Ramon Andrade De Mello, Nathália Moisés Neves, Giovanna Araújo Amaral, Estela Gudin Lippo, Pedro Castelo-Branco, Daniel Humberto Pozza, Carla Chizuru Tajima, Georgios Antoniou
Format:	Article
Language:	English
Published:	MDPI AG 2020-06-01
Series:	Journal of Clinical Medicine
Subjects:	NSCLC MET targeted therapy pharmacogenomics predictive biomarker
Online Access:	https://www.mdpi.com/2077-0383/9/6/1918

Similar Items

MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target
by: Gianluca Spitaleri, et al.
Published: (2023-09-01)

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
by: Kaiwen Wang, PharmD, et al.
Published: (2023-08-01)

An Italian Multicenter Perspective Harmonization Trial for the Assessment of MET Exon 14 Skipping Mutations in Standard Reference Samples
by: Paolo Bironzo, et al.
Published: (2023-02-01)

cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance
by: Nele Van Der Steen, et al.
Published: (2015-03-01)

Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies
by: Sally C.M. Lau, MD, MPH, et al.
Published: (2023-10-01)

Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC
by: Jan Trøst Jørgensen, et al.
Published: (2022-04-01)

The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC
by: Tejas Patil, MD, et al.
Published: (2024-02-01)

Overview of Molecular Detection Technologies for <i>MET</i> in Lung Cancer
by: Carina Heydt, et al.
Published: (2023-05-01)

MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC
by: Logan C. Tyler, et al.
Published: (2022-11-01)

Meeting an un-MET need: Targeting MET in non-small cell lung cancer
by: Elena Michaels, et al.
Published: (2022-10-01)

Interstitial lung disease associated with capmatinib therapy in a patient with non‐small cell lung cancer harboring a skipping mutation of MET exon 14
by: Hiroaki Kanemura, et al.
Published: (2021-02-01)

Discovery of LAH-1 as potent c-Met inhibitor for the treatment of non-small cell lung cancer
by: Lijie Sima, et al.
Published: (2024-12-01)

The Emerging Role of the c-MET-HGF Axis in Non-small Cell Lung Cancer Tumor Immunology and Immunotherapy
by: Helen F. Titmarsh, et al.
Published: (2020-02-01)

MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities
by: Kang Qin, et al.
Published: (2023-01-01)

Experience of treatment of a patient with non-small cell lung cancer with met exon 14 skipping
by: M. O. Mandrina, et al.
Published: (2021-08-01)

The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer—A Narrative Review
by: Robert Hsu, et al.
Published: (2023-07-01)

MET Inhibition in Non-Small Cell Lung Cancer
by: Shabnam Rehman, et al.
Published: (2019-03-01)

New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC
by: Nam Ah Kim, et al.
Published: (2020-02-01)

The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer
by: Ting He, et al.
Published: (2022-08-01)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
by: Yu Yao, et al.
Published: (2023-01-01)

Mesothelin promotes brain metastasis of non-small cell lung cancer by activating MET
by: Shengkai Xia, et al.
Published: (2024-04-01)

Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report
by: Molly Wilgucki, DO, et al.
Published: (2022-10-01)

Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities
by: Wen-Yueh Hung, et al.
Published: (2018-11-01)

Use of savolitinib as neoadjuvant therapy for non–small cell lung cancer patient with MET exon 14 skipping alterations: A case report
by: Yu Zhang, et al.
Published: (2022-09-01)

Case report: Response to Savolitinib/EGFR-TKI combination in NSCLC patients harboring concurrent primary MET amplification/overexpression and EGFR mutation
by: Xiaolin Ren, et al.
Published: (2024-02-01)

MET Exon 14 Variants in Non-Small Cell Lung Carcinoma: Prevalence, Clinicopathologic and Molecular Features
by: Lisi Yuan, et al.
Published: (2023-02-01)

The potential role of HGF-MET signaling and autophagy in the war of Alectinib versus Crizotinib against ALK-positive NSCLC
by: Xing Huang
Published: (2018-02-01)

Genome-wide analysis identify novel germline genetic variations in ADCY1 influencing platinum-based chemotherapy response in non-small cell lung cancer
by: Chenxue Mao, et al.
Published: (2022-03-01)

Liquid Biopsy in <i>EGFR</i>-Mutated Advanced NSCLC from T790M to <i>MET</i> Amplification: Clinical Implications and Possibilities in the Resistance Setting
by: Luigi Della Gravara, et al.
Published: (2023-04-01)

MET fusions are targetable genomic variants in the treatment of advanced malignancies
by: Dantong Sun, et al.
Published: (2024-01-01)

Aggregation of lipid rafts activates c-met and c-Src in non-small cell lung cancer cells
by: Juan Zeng, et al.
Published: (2018-05-01)

Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy
by: Fei-fei Gu, et al.
Published: (2016-08-01)

Design of New Derivatives of Dimedone Molecules Using QSAR and Docking Molecular
by: Khaoula Mkhayar, et al.
Published: (2022-11-01)

Tackling CASMI 2012: Solutions from MetFrag and MetFusion
by: Steffen Neumann, et al.
Published: (2013-08-01)

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
by: Li Liu, et al.
Published: (2021-06-01)

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
by: Li Liu, et al.
Published: (2021-10-01)

Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC
by: Guang-Ling Jie, et al.
Published: (2023-01-01)

Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma
by: Nichola Cruickshanks, et al.
Published: (2017-07-01)

Research Progresses in the Treatment of NSCLC with MET Gene Variants: A Riview
by: Ran CHEN, et al.
Published: (2022-12-01)

MET Expression Level in Lung Adenocarcinoma Loosely Correlates with <i>MET</i> Copy Number Gain/Amplification and Is a Poor Predictor of Patient Outcome
by: Wei Yin, et al.
Published: (2022-05-01)